Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avineuro Pharmaceuticals, a developer of novel small molecules for unmet medical needs in neurology and psychiatry, has initiated Phase I clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of schizophrenia.
Subscribe to our email newsletter
The results of Phase I studies are expected to be available in April 2009. Based on these and other results, Avineuro Pharmaceuticals plans to advance AVN-211 into Phase II clinical trials in the second quarter of 2009.